We have located links that may give you full text access.
Noninvasive Prenatal Screening for Fetal Sex Chromosome Aneuploidies at Two Next-Generation Sequencing Platforms.
BACKGROUND: Non-invasive prenatal testing (NIPT) has been widely used for detecting fetal trisomy 13, 18 and 21 and sex chromosome aneuploidies (SCAs), but few studies have been published comparing the performance of NIPT for fetal SCAs between different next-generation sequencing platforms.
METHOD: Retrospective analysis of prospectively collected NIPT data at two next-generation platforms (Proton and Illumina) from Center for Reproduction and Genetics, The Affiliated Suzhou Hospital of Nanjing Medical University was performed, and the Patients identified as NIPT positive of SCAs were offered prenatal fetal chromosomal karyotyping.
RESULTS: A total of 40750 pregnant women agreed to undergo NIPT at two platforms, 38 patients (0.32%) revealed fetal SCAs positive at Proton sequencing platform, and 163 patients (0.56%) showed fetal SCAs positive at Illumina sequencing platform, a total of 201 patients (0.49%) demonstrated positive NIPT results for fetal SCAs. The results of fetal karyotyping revealed 16/28 (57.1%) and 38/103(36.9%) true positive patients at Proton and Illumina sequencing platforms. The over specificity and positive predictive value are 99.90% and 57.1% for Proton and 99.78% and 36.9% for Illumina. SCAs were present in one of every 614 individuals considered in this study.
CONCLUSION: There are no significant differences in detecting SCAs at two next generation sequencing platforms, and NIPT might be an effective strategy to prevent SCAs.
METHOD: Retrospective analysis of prospectively collected NIPT data at two next-generation platforms (Proton and Illumina) from Center for Reproduction and Genetics, The Affiliated Suzhou Hospital of Nanjing Medical University was performed, and the Patients identified as NIPT positive of SCAs were offered prenatal fetal chromosomal karyotyping.
RESULTS: A total of 40750 pregnant women agreed to undergo NIPT at two platforms, 38 patients (0.32%) revealed fetal SCAs positive at Proton sequencing platform, and 163 patients (0.56%) showed fetal SCAs positive at Illumina sequencing platform, a total of 201 patients (0.49%) demonstrated positive NIPT results for fetal SCAs. The results of fetal karyotyping revealed 16/28 (57.1%) and 38/103(36.9%) true positive patients at Proton and Illumina sequencing platforms. The over specificity and positive predictive value are 99.90% and 57.1% for Proton and 99.78% and 36.9% for Illumina. SCAs were present in one of every 614 individuals considered in this study.
CONCLUSION: There are no significant differences in detecting SCAs at two next generation sequencing platforms, and NIPT might be an effective strategy to prevent SCAs.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app